Dymon Asia Capital Singapore PTE. LTD. Sells 7,050 Shares of Johnson & Johnson $JNJ

Dymon Asia Capital Singapore PTE. LTD. lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 58.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 4,950 shares of the company’s stock after selling 7,050 shares during the period. Dymon Asia Capital Singapore PTE. LTD.’s holdings in Johnson & Johnson were worth $1,024,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the business. Avid Wealth Partners LLC bought a new position in Johnson & Johnson in the 4th quarter valued at $204,000. Brown Advisory Inc. grew its position in Johnson & Johnson by 3.0% in the 4th quarter. Brown Advisory Inc. now owns 984,507 shares of the company’s stock valued at $203,744,000 after acquiring an additional 28,392 shares during the last quarter. AFT Forsyth & Company Inc. grew its position in Johnson & Johnson by 1.3% in the 4th quarter. AFT Forsyth & Company Inc. now owns 7,799 shares of the company’s stock valued at $1,614,000 after acquiring an additional 100 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its position in Johnson & Johnson by 8.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 2,508,926 shares of the company’s stock valued at $519,222,000 after acquiring an additional 194,456 shares during the last quarter. Finally, Atlas Capital Advisors Inc. bought a new position in Johnson & Johnson in the 4th quarter valued at $1,194,000. Institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is currently owned by insiders.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson agreed to pay about $1 billion for Firefly Bio technology, a bet on improving treatment options for one of cancer’s most hard-to-target areas. Article Title
• Positive Sentiment: J&J also reported encouraging late-stage results for IMAAVY in warm autoimmune hemolytic anemia, reinforcing the company’s pipeline momentum in rare diseases. Article Title
• Positive Sentiment: Analysts and commentators highlighted J&J as a defensive healthcare name with attractive valuation and dividend appeal, which can support buying interest in a volatile market. Article Title
• Neutral Sentiment: Jim Cramer mentioned J&J while favoring healthcare over technology, which is a sentiment tailwind but not a direct company-specific catalyst. Article Title
• Neutral Sentiment: Johnson & Johnson expanded U.S. availability of its TECNIS PureSee cataract lens, a positive commercial update but likely a smaller stock mover than the acquisition and pipeline news. Article Title
• Negative Sentiment: Ongoing talc-related legal headlines remain an overhang and could limit upside if investors focus back on litigation risk. Article Title

Wall Street Analysts Forecast Growth

Several equities analysts have commented on JNJ shares. Morgan Stanley set a $283.00 price objective on Johnson & Johnson in a research report on Wednesday, April 15th. Rothschild & Co Redburn upped their price objective on Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a research report on Thursday, February 19th. HSBC increased their price target on Johnson & Johnson from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Royal Bank Of Canada reissued an “outperform” rating and set a $265.00 price target on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Finally, Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Twenty research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $253.04.

Johnson & Johnson Price Performance

JNJ opened at $240.57 on Friday. Johnson & Johnson has a 12-month low of $149.04 and a 12-month high of $251.71. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The business’s fifty day simple moving average is $231.51 and its 200-day simple moving average is $227.20. The company has a market capitalization of $579.10 billion, a price-to-earnings ratio of 27.81, a PEG ratio of 2.36 and a beta of 0.26.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. During the same quarter in the prior year, the company earned $2.77 EPS. The business’s revenue was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were given a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, May 26th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a yield of 2.2%. Johnson & Johnson’s dividend payout ratio is 61.97%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.